Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Josep Tabernero, Robin Van Geel, Tormod Kyrre Guren, Rona D. Yaeger, Anna Spreafico, Jason Edward Faris, Takayuki Yoshino, Yasuhide Yamada, Tae Won Kim, Johanna C. Bendell, Martin H. Schuler, Heinz-Josef Lenz, Ferry Eskens, Jayesh Desai et al | ||||||||||||
Title | Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC). | ||||||||||||
|
|||||||||||||
URL | http://meetinglibrary.asco.org/content/166237-176 | ||||||||||||
Abstract Text | J Clin Oncol 34, 2016 (suppl; abstr 3544) |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|